Atlas Trials

PARP-inhibitor on Advanced Metastatic Breast Cancer in Germline PALB2 Mutations Carriers

Clinical trial NCT05232006 · NOT_YET_RECRUITING

Trial details

NCT number
NCT05232006
Sponsor
Assistance Publique - Hôpitaux de Paris
Status
NOT_YET_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Metastatic Breast Cancer in Germline-PALB2 Mutations Carriers
Start date
2022-05-01
Primary completion
2024-09-01
Enrollment
12

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.